| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.26 | 1e-13 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.2 | 7e-09 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.2 | 7e-09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.23 | 2e-06 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.23 | 6e-06 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.22 | 5e-05 |